Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Appointed director
ADIAL PHARMACEUTICALS, INC. (ADIL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Schuyler Kevin (Director) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Bought 700 shares @ $2.74, valued at $1.9k
10/02/2023 ARS Form ARS - Annual Report to Security Holders:
09/26/2023 8-K Quarterly results
08/23/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "ADIAL PHARMACEUTICALS, INC. PRESS RELEASE DATED AUGUST 23, 2023"
08/21/2023 8-K Quarterly results
Docs: "PRESS RELEASE, ISSUED BY ADIAL PHARMACEUTICALS, INC. ON AUGUST 21, 2023"
08/21/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/18/2023 8-K Quarterly results
08/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/04/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "State of Delaware Secretary of State Division of Corporations Delivered 08:03 AM 08/03/2023 FILED 08:03 AM 08/03/2023 SR 20233153666 - File Number 6439279 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION",
"Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’ s Minimum Bid Price Requirement and Reduce the Public Float Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023"
07/28/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/27/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
07/13/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
07/10/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
06/09/2023 8-K Investor presentation
Docs: "ADIAL PHARMACEUTICALS, INC. INVESTOR PRESENTATION DATED JUNE 9, 2023"
06/02/2023 4 Johnson Bankole A. (Director) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 40,000 options @ $0.3025, valued at $12.1k
06/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "PURCHASE AGREEMENT PURCHASE AGREEMENT , dated as of May 31, 2023, by and between ADIAL PHARMACEUTICALS, INC., a Delaware corporation , and ALUMNI CAPITAL LP, a Delaware limited partnership . RECITALS"
05/25/2023 4 Truluck Joseph (CFO) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 157,500 shares @ $0
Granted 125,000 options to buy @ $0.3025, valued at $37.8k
05/25/2023 4 Stilley William B. III (Director) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 240,800 shares @ $0
Granted 50,000 options to buy @ $0.3025, valued at $15.1k
05/25/2023 4 Schuyler Kevin (Director) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 50,000 options to buy @ $0.3025, valued at $15.1k
05/25/2023 4 Newman James W. Jr. (Director) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 50,000 options to buy @ $0.3025, valued at $15.1k
05/25/2023 4 Goodman Tony (Director) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 50,000 options to buy @ $0.3025, valued at $15.1k
05/25/2023 4 Gilliland Robertson H. (Director) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 50,000 options to buy @ $0.3025, valued at $15.1k
05/25/2023 4 Claiborne Cary J (CEO) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 420,000 shares @ $0
Granted 300,000 options to buy @ $0.3025, valued at $90.8k
05/25/2023 4 Anderson J. Kermit (Director) has filed a Form 4 on ADIAL PHARMACEUTICALS, INC.
Txns: Granted 50,000 options to buy @ $0.3025, valued at $15.1k
05/24/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
05/12/2023 8-K Quarterly results
Docs: "PRESS RELEASE, ISSUED BY ADIAL PHARMACEUTICALS, INC. ON MAY 12, 2023"
05/10/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "RE: Notice of Option Exercise",
"Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’ s Assets and Business"
04/13/2023 8-K Quarterly results
03/31/2023 8-K Quarterly results
Docs: "Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update"
03/29/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/21/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Master Services Agreement between Adial Pharmaceuticals, Inc. and The Keswick Group, LLC",
"Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder"
03/07/2023 8-K Investor presentation
Docs: "ADIAL PHARMACEUTICALS, INC. PRESS RELEASE DATED MARCH 6, 2023",
"ADIAL PHARMACEUTICALS, INC. INVESTOR PRESENTATION DATED MARCH 7, 2023"
03/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/06/2023 D Form D - Notice of Exempt Offering of Securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy